hydroxychloroquine has been researched along with Osteoporotic Fractures in 2 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Osteoporotic Fractures: Breaks in bones resulting from low bone mass and microarchitectural deterioration characteristic of OSTEOPOROSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " These studies provide a compelling case for a re-evaluation of the long-term use of glucocorticoids in SLE, focusing on minimizing glucocorticoid exposure as part of the strategy to improve long-term outcomes." | 2.55 | It hasn't gone away: the problem of glucocorticoid use in lupus remains. ( Apostolopoulos, D; Morand, EF, 2017) |
| "One objective in the treatment of systemic lupus erythematosus (SLE) disease activity is to reduce long-term rates of organ damage." | 1.48 | Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort. ( Magder, LS; Petri, M, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Petri, M | 1 |
| Magder, LS | 1 |
| Apostolopoulos, D | 1 |
| Morand, EF | 1 |
1 review available for hydroxychloroquine and Osteoporotic Fractures
| Article | Year |
|---|---|
It hasn't gone away: the problem of glucocorticoid use in lupus remains.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Azathioprine; Cardiovascular Diseases; Cata | 2017 |
1 other study available for hydroxychloroquine and Osteoporotic Fractures
| Article | Year |
|---|---|
Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort.
Topics: Adult; Antirheumatic Agents; Cardiomyopathies; Cataract; Cohort Studies; Diabetes Mellitus; Disease | 2018 |